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Abstract: Selectively targeted nanoscale drug delivery systems have recently emerged as 
promising intravenously therapeutic option for most chronic joint diseases. Here, a newly 
synthetized dodecapeptide (GE11)-polylactide-co-glycolide (PLGA)-based conjugate was used to 
prepare smart nanoparticles (NPs) intended for intra-articular administration and for selectively 
targeting Epidermal Growth Factor Receptor (EGFR). GE11-PLGA conjugate-based NPs are 
specifically uptaken by EGFR-overexpressed fibroblast; such as synoviocytes; which are the 
primarily cellular component involved in the development of destructive joint inflammation. The 
selective uptake could help to tune drug effectiveness in joints and to decrease local and systemic 
side effects. Dexamethasone (DXM) is a glucorticoid drug commonly used in joint disease 
treatment for both systemic and local administration route. In the present research; DXM was 
efficiently loaded into GE11-PLGA conjugate-based NPs through an eco-friendly nanoprecipitation 
method set up for this purpose. DXM loaded GE11-PLGA conjugate-based NPs revealed 
satisfactory ex vivo cytocompatibility; with proper size (≤150 nm) and good dimensional stability 
in synovial fluid. Intra-articular formulation was developed embedding DXM loaded GE11-PLGA 
conjugate-based NPs into thermosetting chitosan-based hydrogel; forming a biocompatible 
composite hydrogel able to quickly turn from liquid state into gel state at physiological 
temperature; within 15 min. Moreover; the use of thermosetting chitosan-based hydrogel extends 
the local release of active agent; DXM. 
Keywords: EGFR targeting; GE11 peptide; PLGA-PEG nanoparticles; chitosan thermosetting 
hydrogel; intra-articular injection 
 
1. Introduction 
Corticosteroid intra-articular (IA) injection is a long-established treatment for patients with 
chronic and non-curable joint diseases, such as rheumatoid arthritis (RA) and most different 
arthritis-related forms (i.e., osteoarthritis, a chronic RA-like inflammatory arthritis, post-traumatic 
arthritis or osteoarthritis, and pseudo gout, an acutely painful inflammatory condition) [1–4]. 
Although chronic joint diseases differ in etiology and relative risk factors, symptoms, 
prognoses, and treatments, growing numbers of systemic administered drugs can be employed to 
manage, alone or in combination, the joint disorders [5]. Non-steroidal anti-inflammatory drugs 
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(NSAIDs), glucocorticoids (GCs), opioids, anti-rheumatic agents (i.e., methotrexate, 
hydroxychloroquine, sulfasalazine, and clodronate), and more recently biological agents (i.e., 
adalimumab, infliximab, and etanercept) are commonly used. 
Currently, the conventional clinical treatment is based on lifelong progressive drug 
administration; nevertheless, it is associated with several drawbacks, including high dose and 
frequency of systemic drug administration, as well as unavoidable systemic adverse effects, such as 
gastro-intestinal, ocular, hepatic and renal toxicity, infections, cardiovascular risk and anaphylaxis 
[6–10]. To date, all recommended treatment protocols fail to shut down disease progression, and 
consequently the main goal of alternative approaches remains to reduce pain, inflammation and 
hinder further destruction to the joints [11]. 
Since the poor efficacy of systemic treatments in chronic joint diseases is primarily due to the 
low drug availability within articular joints, IA administration could offer an interesting therapeutic 
strategy to increase drug concentration at the site of action, minimizing overall systemic exposure 
[4,12]. However, the main limitation of delivering drugs directly into joint cavities is their rapid 
extravasation from the leaky barrier of the inflamed synovia. The half-life of small drug molecules, 
such as GCs or NSAIDs, which successfully provide symptomatic relief in established RA and 
RA-like inflammatory arthritis, has been reported to be in the range of 1–2 h [13,14]. Hence, the 
reduced retention time of therapeutic agents in the targeted tissue requires frequent injections, 
which are associated with both risk of infection and/or joint disability and unsatisfactory patient 
compliance [4]. Additionally, repeated IA administrations of GCs could cause permanent damages 
to the articular cartilage, and systemic adverse events cannot be fully avoided; precautions should 
be observed in patients with concomitant diseases such as hypertension or diabetes mellitus [5,15]. 
In the attempt to obtain a long-lasting release of therapeutic agents in the synovial cavity 
through IA administration, different drug delivery systems have been extensively investigated, 
such as solid lipid particles, polymeric microparticles (MPs) and nanoparticles (NPs) and their 
combination (NPs-in-MPs), drug–polymer conjugates, hydrogels, and in situ hydrogels as such or 
containing conventional MPs or NPs [4,16–23]. Overall, conventional nanoscale drug delivery 
system-based approaches appear very promising because IA administration appears to be simple 
and better penetration into cartilage tissue is achieved [4]. NP sizes (40–200 nm), as well as polymer 
features, such as charge, hydrophilicity and stiffness, should prolong their residence time in 
synovial fluid and improve cartilage uptake as well as therapeutic efficacy [4,18]. In particular, 
positively charged NPs were exploited to prolong the retention time in the synovial cavity through 
electrostatic interactions of positively charge NPs with endogenous hyaluronic acid (negatively 
charged). Moreover, the electrostatic interactions between NPs and the negatively charged 
constituents of cartilage facilitate NPs cartilage uptake. 
The rationale of this work was to exploit the high expression of Epidermal Growth Factor 
Receptor (EGFR) in fibroblast-like synoviocytes, which are the cellular component involved in the 
initiation and perpetuation of destructive joint inflammation [24–27]. The objective was to 
formulate an EGFR-targeting nanoparticulate-based delivery system suitable for the prolonged, 
selective delivery, by IA injection, of drugs inside inflamed synovial fluid. The EGFR-targeting 
nanoparticulate-based delivery system was designed exploiting the high expression of EGFR in 
fibroblast-like synoviocytes, which are the primarily cellular component involved in the initiation 
and perpetuation of destructive joint inflammation [24–27]. 
In a previous study [28], EGFR-targeting poly-lactide-co-glycolide (PLGA)-based conjugate has 
been synthetized by covalently linking PLGA, biodegradable polymer approved by FDA for 
parenteral administration in humans, to GE11 [29,30]. GE11 is a dodecapeptide and it is identified 
as one of the most efficient EGFR allosteric ligand with no evidence of mitogenic activity and it is 
able to induce receptor-mediated internalization of liposomes and nanostructures. This new 
polymeric conjugate, GE11-PLGA, was usefully employed for developing selective EGFR-targeting 
NPs characterized by stealth properties provided by the using of PEGylated PLGA polymer 
(PEG-PLGA) in the polymeric blending, by enhanced stability in human plasma and good 
cytocompatibility [31]. GE11-PLGA/PEG-PLGA blend NPs were chosen for preparing 
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EGFR-targeting NPs intended for IA administration. The selection of blending was supported by 
our preliminary results and the excellent in vivo biocompatibility demonstrated for PEGylated PLA 
derivatives-based microspheres [32]. GE11-PLGA/PEG-PLGA blend NPs were loaded with DXM, 
which is the GC representative drug frequently used in the treatment of several inflammatory and 
autoimmune joint diseases by IA or systemic administration [22,33–37]. 
DXM loaded GE11-PLGA/PEG-PLGA blend NPs were incorporated into thermosensitive 
polymer solution which is in the liquid state at room temperature and turns into gel state at 
physiological temperature, forming a depot formulation in articular joints. The combination of 
DXM loaded GE11-PLGA/PEG-PLGA blend NPs with thermosensitive polymer solution provides 
an effective approach to further reduce the leakage of NPs from the synovial fluid. Chitosan (CS) is 
a natural polymer widely used for preparing in situ thermosensitive hydrogels with peculiar 
advantages, such as biocompatibility, biodegradability non-toxicity, muco-adhesion and 
antibacterial properties [38–40]. CS and β-glycerophosphate (βGP) were used to developed the 
composite in situ gelling delivery system (CS/βGP-NPs) by mixing DXM loaded 
GE11-PLGA/PLGA-PEG blend NPs into the CS-based thermosensitive solution (CS/βG) [41–44]. 
Syringeability and cytocompatibility were also evaluated on CS/βGP-NPs formulation. 
2. Results and Discussion 
2.1. GE11-PLGA/PEG-PLGA Blend Nanoparticles Loaded with DXM 
The efficient loading of DXM inside PLGA-based NPs is a challenging key point [45]. 
Gomez-Gaete et al. particularly investigated many parameters, such as: (i) the effect of PLGA 
composition; (ii) the choice of organic solvent and its evaporation rate during NPs formation; (iii) 
the saturation of the continuous phase; (iv) the addition of a lipid polymer; and (v) the initial mass 
of DXM respect to polymer mass. The highest drug loading (230 μg/100 mg polymer) was obtained 
using 100 mg of PLGA (75:25 relative lactide:glycolide composition) in a mixture of 
acetone-dichloromethane at ratio 1:1 (v:v) and using 10 mg of initial DXM. 
Starting from these considerations and from results published in our previous work [28,31], DXM 
loaded GE11-PLGA/PEG-PLGA blend NPs were prepared using a 1:10 weight ratio of DXM respect to 
the polymer matrix which is composed by 1:1 ratio (w:w) blending of GE11-PLGA and PEG-PLGA. In 
both copolymers, PLGA was characterized by 75:25 relative lactide:glycolide composition. 
To obtain satisfactory DXM encapsulation, DXM loaded GE11-PLGA/PEG-PLGA blend NPs 
were prepared dissolving DXM in Ethanol (0.7 mL) and mixing it with polymer solution in DMSO 
followed by NPs preparation. Results reported in Table 1 show that the loading of DXM using 
Ethanol to DXM solvent was very poor (Batch #DXM2, 280 ± 6 μg of DXM/100 mg of NPs). This 
finding could be due to the rapid diffusion of Ethanol in the aqueous continuous phase (PVA, 1% 
w/v) causing the fast leakage of DXM outside the polymeric matrix during the precipitation phase. 
Other solvents were used in combination with DMSO, in particular, CH2Cl2 (Batch #DXM3) 
and ethyl acetate (Batch #DXM4). These solvents are poorly miscible with water and they were used 
to dissolve DXM before adding to the polymeric solution in DMSO. While with CH2Cl2 the drug 
loading was not significantly improved (Batch #DXM3, 240 ± 6 μg of DXM/100 mg NPs), with ethyl 
acetate good drug loading was achieved (Batch #DXM4, 785 ± 1 μg of DXM/100 mg NPs). 
The continuous phase saturation with salt was not useful in achieving satisfactory DXM 
loading (Batch #DXM5, 170 ± 16 μg of DXM/100 mg NPs) confirming data reported in the literature 
and relative to other polymer/DXM solvent mixture [45]. 
According to these results, ethyl acetate was selected as well-performing DXM solvent in NPs 
preparation procedure. It is worth noting that ethyl acetate as well as DMSO may be regarded in 
Class III (ICH Q3C “Impurities: guideline for residual solvents”) as less toxic and lower risk to 
human health. The use of such safe solvents is highly desirable for eco-friendliness of 
pharmaceutical manufacturing processes. 
As shown in Table 1, no significant modifications of NPs size were highlighted when DXM 
was added to the NPs formulations, NPs mean size was about 150 nm and consequently suitable for 
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EV injection. Very satisfactory PDIs were recorded (about 1.5) highlighting a narrow size 
distribution for the NPs batches. All NPs batches were characterized by a negative zeta potential 
(about −25 mV, Table 1). 
Table 1. Physicochemical properties of GE11-PLGA/PEG-PLGA blend NPs batches: DXM content, 
size, polydispersity index (PDI) and Zeta potential (Z pot). Results are expressed as mean ± standard 
deviation (sd). 
Batch 
# 
DXM 
Solvent 
Continuous Phase Composition 
Drug Content 
(g DXM/100 mg NPs) 
Size ± sd 
(nm) 
PDI ± sd 
Z Pot ± sd 
(mV) 
PVA  
(%, w/v) 
NaCl 
(%, w/v) 
1 - 1 - - 143.9 ± 5.0 0.145 ± 0.030 −24.9 ± 3.4 
DXM2 Ethanol 1 - 280 ± 6.0 151.3 ± 6.5 0.133 ± 0.028 −26.7 ± 2.6 
DXM3 CH2Cl2 1 - 240 ± 6.0 144.4 ± 5.2 0.129 ± 0.029 −21.8 ± 5.5 
DXM4 Ethyl acetate 1 - 785 ± 1.0 145.7 ± 4.5 0.147 ± 0.032 −23.1 ± 5.3. 
DXM5 - 1 5 170 ± 16 151.6 ± 2.9 0.126 ± 0.033 −25.9 ± 2.9 
Batch #1, placebo NPs, is used as reference. 
Figure 1 shows TEM image of DXM loaded NPs (Batch #DXM5). DXM loaded 
GE11-PLGA/PEG-PLGA blend NPs were spherical and regular in shape. No aggregation 
phenomena have been observed by TEM analysis; data are consistent with the narrow size 
distribution detected by DLS analysis. TEM images were further elaborated by Jmicrovision 
software to measure particles size. NPs mean size of 140.40 ± 43.56 nm was calculated confirming 
the results obtained by DLS analysis. 
 
Figure 1. TEM photomicrograph of DXM loaded GE11-PLGA/PEG-PLGA blend NPs (Batch #DXM5). 
Magnification: 50,000×. 
Process yield of about 80% was estimated for the NPs set-up preparation method. 
2.2. Nanoparticles Dimensional Stability in Synovial Fluid 
Fluorescence Single Particle Tracking (fSPT) is a reliable technique used for evaluating possible 
aggregations of NPs when they become in contact with biological fluids. In particular, it measures 
modifications of NPs diffusion coefficient in different biological media compared with the diffusion 
coefficient in water. These modifications could be due the deposition of protein corona which is 
responsible of poor stability and fast aggregation of NPs [46]. 
GE11-PLGA/PEG-PLGA blend NPs are intended to be administered locally by IA route. The final 
goal of the present research was to treat by in situ treatment different diseases, such as undifferentiated 
arthritis, limiting the systemic side effects of selected drugs (GCs). The highest efficacy of the 
nanoparticulate device is guaranteed, unless no aggregation occurs in the site of administration [47]. To 
this end, the evaluation of NPs stability in synovial fluid becomes the fundamental formulative aspect 
and fSPT is the only technique available to study the stability of NPs in undiluted biological fluids. 
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Analyses were performed using fluorescently-labeled NPs formulations [31], both GE11-targeted 
and untargeted blend NPs prepared using PEG-PLGA previously labeled with PEG-PLGA-RhB have 
been investigated. The NPs suspension was diluted in synovial fluid withdrawn from patients 
affected by undifferentiated arthritis; the diluted suspension was stored for 4 h at 37 °C. At specified 
times (1 and 4 h), NPs sizes were measured through fSPT and compared to NPs sizes at time zero (t0). 
Considering the high variability between each collected sample, the viscosity of synovial fluid was 
measured each time before fSPT experiment with capillary viscometer. 
As shown in Figure 2a,b, both GE11-PLGA/PEG-PLGA-RhB and untargeted 
PLGA/PEG-PLGA-RhB blend NPs are stable in synovial fluid since no aggregation phenomena 
were observed. The mean size of untargeted PLGA/PEG-PLGA NPs was increased of about 50 nm 
after 1 h of incubation in synovial fluid and no further increase in NPs dimension was noticeable at 
4 h (Figure 2b). 
 
Figure 2. Size distribution of: (a) GE11-PLGA/PEG-PLGA-RhB NPs; and (b) PLGA/PEG-PLGA-RhB 
NPs in synovial fluid. Measurements have been carried out by fSPT technique at time zero (t0), after 
1 h (t1) and 4 h (t4) of incubation in synovial fluid. The stripped blue line corresponds to NPs size 
distribution in water and it was used as control. 
Since NPs dimension is under 350 nm, it can be stated that NPs are stable and the slight increase 
in NPs sizes could be attributed to protein absorption (average diameter: t0 = 130.7 nm; t1 = 181.9 nm; t4 
= 162.8 nm). The increase in NPs sizes is lower if compared to the increase in dimension due to plasma 
protein [31]. Indeed, synovial fluid is an ultra-filtrate of blood, so the composition in terms of proteins 
is the equivalent to the plasma but their concentration is significantly lower compared with the 
plasma, explaining the reduced adsorption of proteins and the small increase of NPs size. 
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These findings were consistent with results obtained for GE11-functionalized NPs (Figure 2a) 
showing a slight increase in NP sizes (average diameter: t0 = 100.9 nm; t1 = 145.6 nm; t4 =130.8 nm) 
not attributable directly to NPs instability. 
In both cases, a slight NPs size increase was revealed when NPs were resuspended in water, 
even if NPs size was much lower than 350 nm, which is probably due to the major hydrated state of 
polymeric NPs when in contact with pure water. 
The data collected by fSPT technique could be considered as conclusive proof of good stability 
of GE11 NPs in synovial fluid and their suitable applicability for IA administration. 
2.3. Cytocompatibility of Nanoparticles 
PLGA and PEG-PLGA are biodegradable and biocompatible polymers approved by FDA for 
parental administration and widely used in drug delivery field; however, it is advisable to verify 
the biological behavior of the new conjugate GE11-PLGA. Cytotoxicity study on placebo 
GE11-PLGA conjugate-based NPs were carried out on Caki1 and A549 cell lines, as overexpressing 
EGFR cell line models, and HUVEC, as control cell line. Cell viability was evaluated by MTS assay 
after 48 h of incubation. Results, plotted in Figure 3, were expressed as cell viability percentage (%) 
compared to the control (CRT, untreated cells). 
GE11-PLGA/PEG-PLGA blend NPs highlighted an excellent cytocompatibility. After 48 h of 
incubation, the cell viability was always higher than 70% for all concentration tested (from 0.1 
μg/mL to 1000 μg/mL). Overexpressing EGFR cell line disclosed a good cell viability ranging from 
128% to 97% and from 153% to 109% for Caki-1 and A549, respectively. The cell viability decreased 
until 70% of the control at the highest concentration tested (100–1000 μg/mL) only with HUVEC cell 
line. As a conclusion, GE11-PLGA/PEG-PLGA blend NPs were found to be safe platform that could 
be use as drug delivery system in wide range of concentration (0.1–1000 μg/mL). 
 
Figure 3. MTS proliferation assay performed on GE11-PLGA/PEG-PLGA blend NPs incubated for 
48 h with Caki1, A549 and HUVEC cell lines. The data represent the mean ± sd (n = 3, independent 
experiment). The results are expressed as viability percentage compared to untreated cells (CRT). 
2.4. Incorporation of DXM Loaded GE11-PLGA/PEG-PLGA Blend Nanoparticles into CS-Based 
Thermosetting Hydrogel 
In situ gelling hydrogels have shown great potential in IA drug delivery [21,23]. These 
hydrogels are easy to handle at room temperature, and they can be readily administered inside the 
joint because they are characterized by good syringeability and injectability. They undergo sol-gel 
transition after administration into the body following their exposure to specific stimuli, such as 
changes in pH or temperature. 
The present work envisages the incorporation of targeted GE11-PLGA/PLGA-PEG blend NPs 
into a CS-based thermosetting hydrogel (CS/βGP). The sol/gel transition of the CS/βGP solution, the 
gelation mechanism, and their control for potential biomedical application were extensively investigated 
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[43,48–50]. The composite hydrogel made of CS/βGP and EGFR-targeted NPs (CS/βGP-NPs) provides a 
useful delivery platform characterized by distinctive features. CS/βGP could represent an optimal 
strategy to locally deliver therapeutic agents inside the joints; CS is a biocompatible polymer which can 
be safely used as delivery device for in situ administration [23,43,44,51]. The gel-like features of CS/βGP 
would be useful to tune DXM and NPs release from hydrogel formulation inside the joint avoiding the 
NPs leakage outside the synovial membrane; moreover, the presence of GE11 on the NPs surface could 
further promote the NPs uptake from EGFR-overexpressing cells improving the selective activity of the 
drug minimizing systemic and local side effects. 
2.4.1. Syringeability of the CS/βGP and CS/βGP-NPs 
Syringeability experiments were performed to study the effect of needle on flow rate of CS/βGP 
and CS/βGP-NPs, at constant pressure of 0.7 bar. Flow rate values higher than 0.4 mL/min are 
comparable to usual injection rate, as indicated in the literature [52,53]. Results are collected in Table 2. 
Table 2. Flow rate values of HA (15 mg/mL aqueous solution), GO-ON®, CS/βGP and CS/βGP-NPs 
using a syringe-needle system with 22 G and 20 G needle. Results are reported as mean ± sd (n = 3 
independent experiments). 
Sample 
Flow Rate Mean Value ± sd  
(mL/min) 
22 G 20 G 
HA 0.30 ± 0.01 5.42 ± 1.95 
GO-ON® 1.21 ± 0.05 6.17 ± 1.80 
CS/βGP 1.73 ± 0.15 6.63 ± 0.82 
CS/βGP-NPs 0.54 ± 0.07 6.18 ± 1.03 
The experiment showed suitable flow rate value for all sample tested when 20 G needle 
diameter is used; in addition, no significant differences were highlighted between CS/βGP and 
CS/βGP-NPs formulations. The flow rate values were 6.63 ± 0.82 mL/min and 6.18 ± 1.03 mL/min for 
CS/βGP and CS/βGP-NPs, respectively (Table 2). CS/βGP and CS/βGP-NPs results were fully 
superimposable to reference products for IA administration, namely, hyaluronic acid aqueous 
solution (HA, 5.42 ± 1.95 mL/min) and GO-ON® (6.17 ± 1.80 mL/min). 
All formulations have been further studied in terms of syringeability using syringe-22 G needle 
system (see Secition 3.2). The results demonstrated that HA was not suitable for syringeability because 
flow rate was <0.4 mL/min (Table 2), while CS/βGP flow rate (1.73 ± 0.15 mL/min, Table 2) was 
comparable to the commercial product GO-ON® (1.21 ± 0.05 mL/min, Table 2). Furthermore, reduction 
in the flow rate was observed for CS/βGP-NPs (0.54 ± 0.07 mL/min) for the 22 G needle system. Both 
CS/βGP and CS/βGP-NPs formulations can be considered suitable for IA administration through 
manual injection using slender needles (20 G–22 G) to improve patient compliance. 
2.4.2. CS/βGP and CS/βGP-NPs Rheological Characterization 
As indicated in the literature, CS/βGP modulates its gelation behavior upon temperature change. 
This behavior has been ascribed to competition among intermolecular interactions, including 
electrostatic and hydrogen bonds which implies gradual removal of protective hydration layer formed 
by the gelling agent around the CS chains. In these conditions, hydrophobic attractive interactions 
occurred among polymer chains leading to gradual increase of CS/βGP gel strength [41–43,48–50]. 
The steady shear behavior of CS/βGP is clearly influenced by the temperature. Figure 4 shows 
the flow curve of CS/βGP at different temperature; at body temperature (37 °C), a noticeable 
increase in viscosity was highlighted at low shear rate (<1 s−1) compared with formulation measured 
at room temperature (25 °C). The difference in viscosity was negligible at high shear rate; data 
could suggest that the increase of temperature enhanced apparent viscosity of CS/βGP triggering 
the temperature-induced gel structure formation which is broken down by highest shear rates. 
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The shear-thinning behavior of CS/βGP was still observed at 25 °C and 37 °C; as the shear rate 
was increased from 0.1 to 100 s−1, the viscosity value dropped 7 and 11 folds for the CS/βGP 
formulation incubated at 25 °C and 37 °C, respectively. 
 
Figure 4. Shear rate viscosity (Pa*s) of thermosensitive CS/βGP formulation as a function of shear 
rate at 37 °C (body temperature, •) and 25 °C (room temperature, □). 
DXM loaded GE11-PLGA/PEG-PLGA NPs affect the extent of shear thinning behavior of 
CS/βGP (Figure 5). Although both formulation existing in liquid form at 25 °C, CS solution 
containing DXM loaded GE11-PLGA/PEG-PLGA NPs showed less remarkable shear-thinning 
behavior over a broad range of shear rate. Mild downfall of shear viscosity from 0.39 Pa*s to 0.24 
Pa*s was detected increasing the shear rate from 0.1 s−1 to 100 s−1. Moreover, considering the shear 
rate values applied on polymeric solution during an injection through 20 G–22 G needles (>100 s−1), 
the NPs loaded CS/βGP highlighted a higher shear viscosity (0.24 Pa*s) than CS/βGP alone (0.15 
Pa*s) approving the results obtained in the previous syringeability test. 
 
Figure 5. Shear rate viscosity (Pa*s) of thermosensitive CS/βGP (□, empty square) and CS/βGP with 
DXM loaded PLGA/PEG-PLGA NPs (X, cross) formulation as a function of shear rate applied (0.1–
100 s−1) at 25 °C. 
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Dynamic mechanical analysis provided the viscoelastic properties of CS/βGP at 25 °C and 37 °C 
measuring the storage modulus (G′) and the loss modulus (G′′) as a function of the oscillatory frequency, 
0.1–10 Hz, which is the frequently tested region in rheological studies. As shown in Figure 6a, CS/βGP 
displayed a loss modulus that was always higher than the loss modulus over the entire frequency range; 
the most remarkable difference between G and G was observed at lower frequencies (<1 Hz) and both 
moduli increased with increasing frequencies. These patterns are common for polymeric solution. At 37 
°C, oscillatory measurement showed that the storage modulus was higher than the loss modulus over 
almost the entire frequency range, as reported in Figure 6b. This phenomenon is consistent with the 
gelation mechanism induced by temperature. 
 
Figure 6. Frequency dependence of storage modulus (G′, •) and loss modulus (G′′, ○) of CS/βGP at: 
25 °C (a); and 37 °C (b). Each modulus was measured between 0.1 and 10 Hz at stress of 0.1 Pa. 
The thermosensitive properties of CS/βGP and CS/βGP-NPs were evaluated by sol/gel transition 
temperature determination. The sol/gel transition temperature (Tgel) corresponds to the temperature at 
which the storage modulus (G′) is equal to the loss modulus (G′′). CS/βGP exhibits a viscoelastic 
liquid behavior with the curve showing the dominance of the loss modulus (G′′ > G′) when the 
temperature is below Tgel (T < Tgel), while the elastic portion became dominant (G′ > G′′), indicating 
clearly the transition into a gel, as temperature increase at T > Tgel. The gelation temperature was 
found to range 40 ± 2 °C and 50 ± 1 °C for CS/βGP and CS/βGP-NPs, respectively (Figure 7). The 
increased gelation temperature of CS/βGP-NPs formulation was probably due to the presence of 
negatively charged NPs which could interact electrostatically with positive amine groups of CS 
polymer preventing polymer chain interactions by steric hindrance during the sol/gel transition. 
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Figure 7. Temperature dependence of storage modulus (G′, •) and loss modulus (G′′, ○) of CS/βGP 
(a) and CS/βGP-NPs (b) formulations. The modulus value was measured between 25 and 60 °C 
(heating rate 5 °C/min, sampling interval = 15 s), at a stress of 0.1 Pa and frequency of 1 Hz. 
The suitability of thermosensitive formulation gelation temperature and reproducibility of 
gel-like behavior in situ was evaluated measuring the sol/gel transition time at 37.5 °C through 
sweep time test. The tests (Figure 8) showed a considerable increase of the gelation time when DXM 
loaded PLGA/PLGA-PEG NPs are incorporated in the formulation. CS/βGP and CS/βGP-NPs 
formulations turned into gel-like state after 5 and 14 min at 37.5 °C, respectively. Gelification times 
longer than 20 min are not suitable for the intended administration goal, as NPs suspended into the 
hydrogel may spread out into the surrounding tissue if hydrogel is not quickly formed. 
Furthermore, once the gelation process began, the moduli gradually increased, indicating the gel 
network formation is progressive and it was not completed during the measurement time. 
 
Figure 8. Time dependence of storage modulus (G′, •) and loss modulus (G′′, ○) of CS/βGP (a) and 
CS/βGP-NPs (b) formulations. The modulus was measured at 37.5 °C (sampling interval, 5 s) at a 
stress of 0.1 Pa and frequency of 1Hz. 
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No difference in rheological behaviors was highlighted with placebo GE11-PLGA-PEG-PLGA 
NPs CS thermogelling formulation 
2.4.3. CS/βGP and CS/βGP-NPs Cytocompatibility 
Cytocompatibility of thermosetting CS-βGP and CS-βGP containing placebo 
GE11-PLGA/PEGPLGA blend NPs (CS-βGP-plNPs) was detected by an indirect test as stated by 
ISO10993-5. The formulations were incubated, after complete gelification in water bath (20 min, at 
37 °C), in fresh cell culture medium (1 mL) at 37 °C for seven days. Incubation media toxicity were 
tested by MTT assay after incubation for 24, 48 and 72 h. 
Results were expressed as cell viability percentage compared to CRT (untreated cells) as a 
function of incubation time (Figure 9). Cell viability of CS-βGP and CS-βGP-plNPs formulations was 
comparable to cells viability of CRT (about 100%) after 24 h of incubation. At Hour 48, CS-βGP and 
CS-βGP-plNPs formulations presented slight drop of cell viability, ranging from 90% to 86%. After 72 
h, cell viability was further reduced; nevertheless, results were higher than 70% compared with CRT. 
No significant differences were observed between CS-βGP and CS-βGP-plNPs formulations. 
These results are the objective evidence of the high biocompatibility of thermosetting CS-βGP 
which is already widely employed in tissue regeneration for the excellent biological properties of 
CS. Additionally, the addition of placebo GE11-PLGA/PEG-PLGA NPs inside the gel had no impact 
on cytocompatibility of composite system CS-βGP-NPs formulation; thus, it can be postulated that 
selected polymers (GE11-PLGA, PLGA-PEG), solvents and process procedure used for preparing 
NPs are safe and this assumption is consistent with data previously published [31]. 
 
Figure 9. Cytotoxicity of CS-βGP and CS-βGP-plNPs evaluated after incubation for 24, 48 and 72 h 
with HDFs. Results are presented as mean ± sd (n = 3, independent experiment). Tukey′s multiple 
comparison reveals no significant differences. CRT is untreated cell used and used as control. 
2.5. DXM Release 
In vitro release test was performed on freeze dried DXM loaded untargeted PLGA/PLGA-PEG 
NPs and GE11-PLGA/PEG-PLGA NPs suspended in Hepes buffer (2 mL, pH 7.0) at 37 °C, to mimic 
inflammatory pathological conditions (Figure 10). NPs formulations are characterized by peculiar 
release profile depending on polymeric composition. 
DXM release from PLGA/PEG-PLGA NPs was very rapid; the complete release of the drug 
was achieved in 60 min, with an initial burst release of about 80% in the first 30 min (Figure 10, 
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dotted line). The high burst release suggests the prevalent drug adsorption on the NPs surface as 
already observed in previous studies [45]. 
DXM release profile from GE11-PLGA/PEG-PLGA NPs is composed by three phases (Figure 
10, solid line). The first phase is characterized by burst release in the first 60 min which consists of 
about 80% of the DXM loaded amount; in the second phase, the release of remaining drug was 
completed in 240 min where the plateau is reached. This release pattern could be partially 
attributed to the amount of DXM not completely loaded in NPs core, to the increased hydrophilicity 
of polymer matrix containing PEG and GE11, and to the reduced Tg of the polymeric matrix due to 
the presence of PEG [31]. Nevertheless, the presence of GE11 seems to allow enhanced dispersion of 
the DXM molecules within the polymer matrix resulting in more prolonged release (within 4 h) 
compared to untargeted PLGA/PEG-PLGA NPs. 
 
Figure 10. DXM release profile from GE11-PLGA/PEG-PLGA NPs (solid line) and PLGA/PEG-PLGA 
NPs (dotted line) under simulated inflammatory pathological conditions (pH7.0) at 37 °C. 
Considering the rapid diffusion of DXM from GE11-PLGA/PEG-PLGA NPs, the studied 
nano-based formulation cannot represent an advantage as therapeutic device for systemic 
administration (e.v. injection) compared to the conventional DXM-based solutions or suspensions 
commonly used in therapy. The almost complete DXM release would be achieved before reaching 
the target tissue, thus the use of DXM-loaded NPs does not result in the reduction of side effects 
due to unspecific activity in healthy tissues. On the contrary, the functionalization of PLGA NPs 
with a targeting agent (GE11), specific for synovial EGFR-overexpressing fibroblasts, could increase 
DXM efficacy inside the joint following IA administration. Moreover, the NPs selective uptake 
could enhance the drug efficacy inside the joint. The chance to tune the NPs release rate from the 
hydrogel, their cellular uptake inside the joints and drug release rate is still challenging. 
In this regard, CS/βGP was chosen as potential vehicle for IA injection of targeted NPs. Figure 
11 shows DXM release profiles from DXM loaded CS/βGP (CS/βGP-DXM) and the composite 
formulation CS/βGP-NPs in which DXM loaded GE11-PLGA/PEG-PLGA blend NPs were 
incorporated into CS/βGP hydrogel. The release test was performed at 37 °C to maintain hydrogel 
integrity for the full term of test. 
The release profile of DXM from CS/βGP is characterized by prolonged release pattern over 24 
h (Figure 11a, dotted line,). No burst release occurred and about 40% of the loaded drug was slowly 
released in the first 2 h reaching about 50% at Hour 5 (Figure 11b). 
The model that best fits release data was evaluated by correlation coefficients (R2). The higher 
correlation coefficient was revealed for Higuchi model, for which a R2 value of 0.9306 was highlighted. It 
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was demonstrated that the DXM release from the gel matrix is diffusion controlled. Korsmeyer–Peppas 
model can be used to express drug release from a swellable thin polymeric gel; the diffusional exponent 
(n) was calculated and it was of 0.6523, indicating an anomalous-Fickian behavior [54]. 
 
Figure 11. (a) DXM release profile from DXM loaded CS/βGP (dotted line) and CS/βGP-NPs (solid 
line) under simulated inflammatory pathological conditions (pH 7.0) at 37 °C until 140 h of 
incubation; and (b) focus on the first 5 h of incubation. 
The composite system CS/βGP-NPs showed (black continue line, Figure 11a,b) triphasic release 
profile (Figure 11a), slightly more rapid release rate could be observed in the first 20 min with 
respect to CS/βGP-DXM formulation, and the plateau phase was recorded at Hour 5, reaching 20% 
of release (Figure 11b). DXM release pattern was then characterized by low DXM release rate up to 
Hour 30 (about 33%, Figure 11a) with following slight increase. CS/βGP-NPs demonstrated the 
ability to prolong DXM drug retention time within 144 h and to reduce its initial burst release. 
Considering the rapid release of DXM from NPs and the prolonged DXM release obtained from 
the composite system CS/βGP-NPs, it is after all realistic to assume that NPs are not quickly released 
from the hydrogel matrix. Nevertheless, unlike DXM and NPs release profiles could take place when 
formulation is injected in vivo. When NPs viscous dispersion embedded in a thermosensitive 
CS-based solution is injected into the joint, NPs potentially have time to partially escape from the CS 
solution because CS dispersion gelification takes about 15 min at body temperature. 
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Hence, considering the GE11-PLGA/PLGA-PEG blend NPs’ good size stability in contact with 
synovial fluid (as previously demonstrated), NPs could be captured by EGFR-overexpressed 
synovial fibroblasts, decreasing their leakage from the joint and contributing to increase drug 
efficacy. This speculative hypothesis can be strengthened by the GE11-targeted NPs fast uptake by 
EGFR-overexpressing cells (≤30 min), as demonstrated by our research group [31] which is 
compliant with the CS/βGP-NPs gelation time. Subsequently, joints movement can promote 
gel-structure breakdown allowing further NPs release from the Cs-based hydrogel. 
3. Materials and Methods 
3.1. Materials 
Poly-(D,L-lactide-co-glycolide) (PLGA, 75:25, Mw 30 kDa) and poly-(D,L-lactide-co-glycolide)block- 
poly(ethileneglycole)block-poly(lactide-co-glycolide) (PLGA-PEG, 75:25, Mw 36 kDa) were purchased 
from Lakeshore Biomaterials (Birmingham, AL, USA). 
Chitosan chloride (CS) pharmaceutical grade (Protosan CL213, Mw 300–350 kDa, deacetylation 
degree 82%, hydrochloric acid content 10–20%) was purchased from FMC BioPolymer AS 
NovaMatrix (Sandvika, Norway); glycerol-2-phosphate disodium salt (β-GP), hyaluronic acid 
sodium salt (HA), from Streptococcus equi (high molecular weight, Mw 1500 kDa) and 
Dexamethasone (DXM) were from Sigma-Aldrich (Saint Louis, MO, USA). GO-ON® (1% sodium 
hyaluronate solution, Class III medical device—Xeditone Pharmaceutical Inc., Mississauga, Ontario, 
Canada) was available on the market. All other reagents, resins and solvents were purchased from 
Sigma-Aldrich (Saint Louis, MO, USA) and/or Merck KGaA (Darmstadt, Germany) and used 
without any further purification; all solvents were of HPLC grade. 
HUVEC (ATCC® CRL-1730™), Caki-1 (ATCC® HTB-46™), A549 (ATCC® CCL-185™) cells and 
Normal, Human, Adult, Primary Dermal Fibroblasts (HDFa) (ATCC® PCS-201-012™) were 
purchased from PromoCell (VWR International PBI s.r.l, Milano, Italy). 
Sinovial fluid was recovered from patients affected by undifferentiated arthritis at the Gent 
University Hospital (Gent, Belgium). 
3.2. Methods 
3.2.1. DXM Loaded GE11-PLGA/PEG-PLGA Blend Nanoparticles Preparation 
Preparation of Placebo Nanoparticles 
GE11 was custom synthetized by Solid Phase Peptide Synthesis according Fmoc methodology 
using a microwave synthetizer (Biotage Microwave SD Initiator, Uppsala, Sweden) on the basis of a 
well established method [28,55]. GE11-PLGA conjugate was synthetized using carbodimmide 
chemistry procedure previously described and set-up [28]. 
GE11-PLGA conjugate-based NPs were prepared following a modified nanoprecipitation 
technique suitably set-up for GE11-PLGA/PEG-PLGA blend NPs by our research group [31]. 
Briefly, NPs were prepared by using a physical mixture of GE11-PLGA and PEG-PLGA 
co-polymers in a 1:1 weight ratio to obtain GE11-PLGA/PEG-PLGA blend NPs. The physical 
mixture of polymers (raw materials) was dissolved in 5 mL of DMSO at final concentration of 15 
mg/mL. The polymeric solution was then poured into continuous phase (10 mL) containing PVA 
(1% w/v), under vigorous stirring. NPs were maintained for 4 h under magnetic stirring (700 rpm) 
to ensure complete curing. They were washed twice with bi-distilled water in a row and recovered 
by ultracentrifugation (30 min, 4 °C, 40,000 rpm; Ultracentrifuge Beckman LE80 equipped with a 
fixed angle rotor Ti70, Beckman Coulter, Pasadena, CA, USA) (Batch #1, Table 1). 
Untargeted PLGA/PEG-PLGA blend NPs were prepared using PLGA and PEG-PLGA in the 
same weight ratio respect to GE11-PLGA conjugate-based NPs. Untargeted NPs were prepared as 
reference, according to the procedure afore described for GE11-functionalized NPs preparation. 
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Each NPs batch was prepared at least in triplicate; at the end, after recovery by centrifugation, 
each NPs batch was suspended in 1 mL of bi-distilled water, frozen at −25 °C overnight and 
freeze-dried at −50 °C, 0.01 bar for 24 h (Lio 5P, Cinquepascal s.r.l., Milan, Italy). Percentage process 
yield was calculated as percent ratio between weighted freeze-dried NPs batch and raw materials 
used in the preparation of each NPs batch. 
Optimization of DXM Loading into GE11-PLGA Conjugate-Based NPs 
The optimization of DXM loading into GE11-PLGA conjugate-based NPs has been performed 
using different approaches. The first approach was based on using different organic solvents, such 
as ethanol (EtOH), Methylene Chloride (DCM) or Ethyl Acetate (EAc). In particular, DXM (7.5 mg) 
was alternatively dissolved in 0.7 mL of each organic solvent (Table 1) before its adding into DMSO 
polymeric solution. The weight ratio between polymeric mixture and DXM was kept constant at 
10:1 w:w (Batches # DXM2-4, Table 1). 
The second approach consisted in increasing the osmotic concentration of the continuous 
aqueous phase. In particular, Batch #DXM5 (Table 1) was prepared adding sodium chloride (NaCl) 
to the PVA aqueous solution at final concentration of 5% w/v. 
All the prepared batches are summarized in Table 1. Each batch was prepared at least in 
triplicate. Process parameters such as polymer concentration, phase volumetric ratio and curing 
conditions were kept unchanged as set up for placebo batches. 
Untargeted PLGA/PEG-PLGA blend NPs loaded with DXM were prepared using the 
previously selected set-up conditions and used as control.  
For each NPs batch, the percent process yield was calculated as percent ratio between weighted 
freeze-dried NPs batch and raw materials used in the preparation of each NPs batch. 
DXM Loading Determination 
DXM loading was determined quantifying loaded DXM directly from freeze-dried 
DXM-loaded NPs powder. Briefly, 5 mg of DXM-loaded NPs were dissolved in DMSO (1 mL) 
under magnetic stirring. Then, 3 mL of methanol were added to DMSO to ensure polymer 
precipitation. The obtained suspension was centrifuged (16,400 rpm, 10 min, 4 °C) to separate 
polymer from DXM. The DXM content in the supernatant was analyzed by HPLC according to an 
optimized method [45]. The analytical conditions are the following: column C18 Zorbax Eclipse 
plus, 4.6 × 15 cm, 5 μm; mobile phase, 40:60 (v:v) Acetonitrile: H2O, flow rate 1 mL/min and 
wavelength 238 nm. The complete run was fixed to 10 min and the DXM peak was detected after 4 
min. The calibration curve was prepared dissolving different amounts of DXM in a mixture of 
DMSO: Methanol at ratio 1:3 (v/v); good linearity between concentration and absorbance was found 
between 0.8 and 26 μg/mL of DXM (y = 52.31x + 1.35, R2 = 0.99977). The results are expressed as 
amount of DXM (μg) in 100 mg of NPs. 
3.2.2. Characterization of Nanoparticles: Morphology, Size and Surface Charge 
NPs shape and morphology were visualized using transmission electron microscopy (TEM 208 
S, Philips, Milan, Italy). GE11-PLGA/PEG-PLGA NPs, after centrifugation, were resuspended in 
water. A small aliquot (15 μL) was stained with 1% (w/v) phosphotungstenic acid (pH 7.0 adjusted 
with NaOH solution, 1 M) for 2 min and then it was immobilized on a copper grids to assess the 
analysis by TEM. TEM micrographs were the elaborated by Jmicrovision 1.0 software (JMicro Visi 
Geneva, Switzerland) to reveal the NPs size. 
Size and size distribution of all prepared NPs batches were further investigated using dynamic 
light scattering (NICOMP 380 ZLS, Particle Sizing Systems—Entegris, Port Richey, FL, USA). 
Measurements were performed on NPs resuspended in bi-distilled water. The zeta potential of NPs 
was evaluated with the same instrument using platinum electrodes; in this case, NPs pellet was 
resuspended in NaCl aqueous solution, 10 mM. The size analyses and surface charge determinations 
were performed in triplicate. 
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3.2.3. Nanoparticles Size stability in Synovial Fluid 
NPs dimensional stability in synovial fluid was assessed using Fluorescence Single Particle 
Tracking (fSPT) [46]. For this purpose, fluorescently-labeled targeted and untargeted 
fluorescently-labeled NPs were also arranged using Rhodamine B (RhB) as fluorescent marker. 
Fluorescent NPs were prepared starting from a physical mixture of GE11-PLGA (or PLGA) and 
PEG-PLGA-RhB conjugate [31], at 1:1 weight ratio, and following the nanoprecipitation method 
described above. The PLGA-PEG-RhB conjugate was prepared according to carbodiimmide 
chemistry, as widely described [56]. 
fSPT experiments were performed on fluorescent NPs samples suspended in synovial fluid 
collected from patient affected by undifferentiated arthritis at the Gent University Hospital (Gent, 
Belgium). The collected synovial fluids were characterized in terms of viscosity through capillary 
viscometer (Capillary viscometer MGW S5, Lauda Brinkmann, Deltran, NJ, USA), and viscosity 
analyses were carried out before fSPT evaluation. 
For the fSPT evaluation, NPs suspensions (10 mg/mL) was diluted 1:300 in PBS. Five microliters of 
NPs suspension were diluted in 45 μL of synovial fluid and incubated for 1 and 4 h at 37 °C in a 
glass-bottom 96-well plate (Greiner Bio-One GmbH, Frickenhausen, Germany). During the incubation 
and measurements, the well plate was sealed with adhesive plates seals (Thermo Scientific, Milan, Italy) 
to avoid evaporation of sample. At the end of the incubation time, the samples were placed on the 
custom-built fSPT set-up and movies were recorded at 5 μm above the bottom of the plate. Videos were 
recorded at 22.5 °C (RT) with the NIS Elements software (Nikon, Tokyo, Japan) driving the CCD camera 
(Cascade II:512, Roper Scientific, Tucson, AZ, USA) and a TE2000 inverted microscope equipped with a 
100_NA1.4 oil immersion lens (Nikon, Tokyo, Japan). Each experiment was performed in triplicate; the 
results are expressed as dimensional distribution of NPs vs. time of incubation in synovial fluid. 
As comparison, analyses were assessed on fluorescently-labelled NPs resuspended in water at 
equal experimental conditions. 
3.2.4. Nanoparticles Cytocompatibility 
Cytotoxicity of GE11-PLGA conjugate-based NPs was determined evaluating cells 
proliferation after incubation with NPs suspension. For this purpose, an MTS test using CellTiter 
96® AQueous One Solution kit (Cell Proliferation Assay, Promega, Madison, WI, USA) was 
performed. The test was performed on Caki1 and A549 cell lines, as overexpressing EGFR cell line 
models, and HUVEC, as control. Cells were seeded in a 96-well plate, 3000–5000 cells/well. NPs 
were resuspended in the cell culture media (RPMI, 10% v/v FBS) at different concentrations (from 
0.1 μg/mL to 1 mg/mL); each NPs suspension was added to the cells and further incubated for 48 h 
at 37 °C, 5% CO2. 
The results of cell proliferation were expressed as a percentage of vital cells respect to the 
control, which is characterized by cells not incubated with NPs. 
3.2.5. Formulation of Thermosetting CS-βGP and CS-βGP-NPs 
CS-βGP was prepared by a combination of chitosan CL213 (CS) and β-glicerophosphate 
solutions (β-GP) [51]. Briefly, 2.4% w/v CS solution in bi-distilled water was sterilized for 15 min in 
autoclave at 121 °C and 1 atm (Autoclave Vapor Matic 770, Milan, Italy). Separately, 58% w/v β-GP 
solution was prepared in bi-distilled water and sterilized by filtration using appropriate filter 
membrane (0.22 μm). Both solutions were cooled down to 4 °C in ice/water bath. β-GP solutions 
(172.4 μL) were dropped into CS solutions (827.6 μL) in a volume ratio of 1:4.8 and were mixed in 
an ice bath for about 1 h to allow the hydrogel forming. 
CS-βGP-NPs formulation was prepared suspending DXM loaded GE11-PLGA/PLGA-PEG blend 
NPs (60 mg) into the β-GP solution, thereafter the obtained suspension has been added into chitosan 
solution, as described before. The amount of NPs (60 mg) was selected considering the DXM loading 
into NPs and the common DXM dose in prompt-release formulation for IA injection [36]. 
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As control, DXM-loaded CS-βGP was prepared directly dissolving DXM in the β-GP solution; 
the amount of DXM used was comparable to amount of DXM effectively loaded into 60 mg of NPs. 
Syringeability of CS-βGP and CS-βGP-NPs 
Solution syringeability is the most critical requirement to consider for an IA injection. The 
syringeability of CS-βGP and CS-βGP-NPs formulations was evaluated using purpose-designed 
instrumentation, PerformusTM III (EFD® Inc., East Providence, RI, USA). The instrument consisted on 
a 5 cc clear luer lock syringe barrel equipped with white piston; for the analysis, needles (EFD® Inc.) 
having different gauge were used, namely 20 G (ID 0.61 mm leigh 25.4 mm) and 22 G (ID 0.41 mm 
leigh 25.4 mm), which are commonly used to improve patient compliance. The syringe was loaded 
with CS-βGP or GE11-PLGA/PLGA-PEG NPs (2 mL) and all tests were carried out at constant 
pressure (0.7 bar). The results were reported as flow rate (mL/min); the proper flow rate for manual 
injection was considered to be higher than 0.4 mL/min [52,53]. 
The syringeability study was broadened to hyaluronate-based formulations normally 
employed for IA visco-supplementation [57]: reference Hyaluronic Acid aqueous solution (HA; Mw 
> 1500 kDa, 1.5% w/v) and GO-ON® (1% w/v high molecular weight hyaluronic acid solution in 
phosphate buffer), the latter an injectable product already available on the market. 
Rheological Behavior of CS-βGP and CS-βGP-NPs 
CS-βGP and CS-βGP-NPs formulations were characterized regarding rheological behavior 
using a Rheometer Kinexus Plus (Alfatest, Milan, Italy) supplemented with circulated 
environmental system for temperature control. The sample (2 mL) was carefully placed within 
cone-plate geometry CP4/40 (1° cone angle, 40 mm diameter) with a gap of about 0.15 mm. The 
solvent trap was used to minimize solvent evaporation during all analysis. 
The temperature flow curve of thermosensitive gels (CS-βGP and CS-βGP-NPs) was 
determined from 25 °C to 37 °C, while shear rate ramp test runs were assessed increasing shear rate 
from 0.1 to 100 s−1 and viscosity value was measured. Each datum is the mean of triplicate analysis. 
Low shear rate behavior can be related to storage stability and levelling, while medium shear 
rate reflects those properties commonly encountered during spreading and pumping. Rubbing and 
spraying are examples of high shear processes. The shear rates applied on CS-βGP and 
CS-βGP-NPs formulations mimic their extrusion through 20–22 G needle (injection phase), using 
flow rate of >0.4 mL/min, as describe in the literature [58]. 
Frequency sweep test was performed to measure the viscoelastic response of samples at 25 °C 
and 37 °C in an oscillation mode (10–0.1 Hz), at constant stress (0.1 Pa). Polymer solution 
viscoelastic properties were assessed by measuring the storage modulus (G′) and loss modulus (G′′) 
representing the elastic behavior and viscous behavior of the materials, respectively. Oscillation 
measurement was carried out in the linear viscoelastic region previously evaluated. Each datum is 
the mean of at least triplicate analysis. 
To evaluate the skill of turning into semisolid hydrogel at body temperature upon injection, 
temperature sweep test was performed at a constant frequency of 1 Hz and stress 0.1 Pa. The 
temperature ranged from 25 °C to 60 °C to pinpoint the gelation temperatures. The sol/gel transition 
temperature (Tgel) corresponds to the intersection of the storage and loss moduli curves, i.e. when they 
are equal. The Kinexus Plus rheometer was also used to characterize the time-dependent changes in 
the elasticity modulus at 37.5 °C, as such process is associated with both the rate and extent of 
thermosensitive gel curing. Time sweep tests were carried out at constant frequency of 1 Hz at 37.5 °C 
and gelation time (tgel) was identified by the intersection of G′ and G′′ curves. 
Cytocompatibility of CS-βGP and CS-βGP-NPs 
Monolayer human adult dermal fibroblasts (HDFs), purchased as primary cells from 
International PBI (Milan, Italy), were cultured in DMEM supplemented with 10% v/v FBS and 1% 
v/v antibiotic solution (100 U/mL penicillin and 100 μg/mL streptomycin), in a 96-well plate (10,000 
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cells/well). Cytocompatibility of thermosetting CS-βGP and CS-βGP containing placebo 
GE11-PLGA/PLGA-PEG NPs (CS-βGP-plNPs) was detected by an indirect test method as stated by 
ISO10993-5 [59]. 
Thermogelling CS solution (1 mL), as such or containing GE11-PLGA/PLGA-PEG NPs (60 mg), 
was placed in a 24-well plate and maintained at 37 °C in a water bath till to complete gelification 
(15–20 min). Fresh cell culture medium (1 mL) was gently added to each well and samples 
incubated at 37 °C for 7 days. 
An aliquot of 100 μL of culture medium was withdrawn and seeded on HDFs with 100 μL of 
fresh DMEM, Samples were incubated at 37 °C, 5% CO2 for 24, 48 and 72 h. At the scheduled times, 
HDFs proliferation was evaluated by an MTT test. All experiments were performed in triplicate 
Cytotoxicity of CS-βGP and CS-βGP-NPs was expressed as a percentage of vital cells respect to 
the control, untreated HDFs, incubated with 200 μL of fresh DMEM. 
3.2.6. DXM Release Tests 
In vitro release tests were carried out on DXM loaded GE11-PLGA/PEG-PLGA and on DXM 
loaded PLGA/PEG-PLGA NPs; these results were considered as reference to evaluate hydrogel-like 
formulations (CS-βGP and CS-βGP-NPs). Briefly, 4.5 mg of NPs were suspended in 2 mL of Hepes 
buffer (pH 7.0 or 7.4) and gently shaken on a bench-top shaker-incubator (See-saw rocker SSL4, 
Stuart® equipment, Stafforshire, Stone,UK) at 37 °C. The release test was performed keeping the 
concentration of DXM under sink conditions (DXM solubility in Hepes buffer was 74 μg/mL). At 
predetermined time points, 1 mL of release medium was withdrawn and replaced with equal volume 
of fresh Hepes buffer. 
DMX release tests from CS-βGP and CS-βGP-NPs were carried out on formulations (1 mL) 
incubated at 37 °C in a water bath for 15–20 min to promote liquid–gel transition phase. Gel-like 
formulations were transferred into Hepes buffer (pH 7.0) and the ratio between loaded DXM and 
the volume of the release medium was adjusted to maintain sink conditions (each hydrogelwas 
soaked into 42 mL of release medium). 
Each sample was analyzed by HPLC following the protocol previously described. DXM 
concentration was determined through a calibration curve between 1.37 and 22 μg/mL of DXM in Hepes 
buffer (y = 49.637x + 0.5841; R2 = 0.9998). Results were expressed as percentage of released DXM respect 
to loaded DXM in the sample vs. time. All experiments were performed in triplicate. 
DXM powder (1.5 mg) was also submitted to a dissolution test in the same experimental 
conditions described above; 100 mL of Hepes buffer were used to keep sink conditions. 
3.2.7. Statistical Analysis 
Statistical significance was determined by application of two-way analysis of variance 
(ANOVA) with a Tukey′s multiple comparison test and of multiple t-test (Holm–Sindak method). 
Differences were considered significant at p value < 0.05. All statistical analyses were 
performed in GraphPad Prism version 5 (GraphPad Software Inc., La Jolla, CA, USA). 
4. Conclusions 
In the present work, an eco-friendly nanoprecipitation method was set up for the preparation 
of GE11-PLGA/PEG-PLGA NPs containing high DXM payload. GE11-PLGA conjugate based NPs 
were characterized by high cytocompatibility, size distribution suitable for IA injection and good 
size stability in synovial fluid. The presence of GE11 peptide covalently linked to PLGA was 
assigned to GE11-PLGA/PEG-PLGA NPs selective targeting features towards EGFR-overexpressing 
fibroblasts involved in chronic joint diseases. 
The present work proved that thermogelling composite system CS/βGP-NPs could be a 
suitable, flexible and promising platform for local treatment of joint diseases. CS/βGP-NPs 
formulation has been well characterized, including syringeability, rheological and thermo-gelation 
behavior. The good cytocompatibility of CS/βGP-NPs is the further evidence of CS/βGP-NPs 
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suitability for biomedical applications. These promising results encourage further in vivo studies to 
identify the most applicable application in the biomedical area. 
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